Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Breast cancer
  • (-) ≠ 2D strain imaging
  • (-) = Zoledronic acid

Search results

  • RSS Feed
(1 - 5 of 5)
Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
Groot, S. de; Pijl, H.; Charehbili, A.; Ven, S. van de; Smit, V.T.H.B.M.; Meershoek-Klein Kranenbarg, E.; ... ; Dutch Breast Canc Res Grp 2019
Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
Article / Letter to editor
metadata only
Strong CD8+lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy
Groot, A.F. de; Blok, E.J.; Charehbili, A.; Engels, C.C.; Smit, V.T.H.B.M.; Dekker-Ensink, N.G.; ... ; Kroep, J.R. 2019
Strong CD8+lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy
Article / Letter to editor
metadata only
Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01)
Charehbili, A.; Hamdy, N.A.T.; Smit, V.T.H.B.M.; Kessels, L.; Bochove, A. van; Laarhoven, H.W. van; ... ; Dutch Breast Canc Res Grp BOOG 2016
Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01)
Article / Letter to editor
metadata only
Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials
Kroep, J.R.; Charehbili, A.; Coleman, R.E.; Aft, R.L.; Hasegawa, Y.; Winter, M.C.; ... ; Kohno, N. 2016
Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials
Article / Letter to editor
metadata only
Optimising preoperative systemic therapy for breast cancer
Charehbili, A. 2015
Optimising preoperative systemic therapy for breast cancer
Doctoral Thesis
some documents under embargo
2017-03-16T00:00:00Z; 2017-03-16T00:00:00Z; 2017-03-16T00:00:00Z
This thesis was divided in two parts. Part I demonstrated benefit of zoledronic acid addition to chemotherapy in terms of pathological response in postmenopausal women. Part II is all about... Show moreThis thesis was divided in two parts. Part I demonstrated benefit of zoledronic acid addition to chemotherapy in terms of pathological response in postmenopausal women. Part II is all about neoadjuvant endocrine therapy, and discusses the optimal duration of this treatment and the information on treatment efficacy that aromatase-inhibitor specific adverse events may provide. Show less